Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7103341 | 0.87 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL7103340 | 0.87 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1942274 | 0.85 | NPSR1 (0.62) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL13269051 | 0.85 | NPSR1 (0.62) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL10208384 | 0.83 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL10689235 | 0.83 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL10689237 | 0.83 | NPSR1 (0.50) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL11655592 | 0.81 | NPSR1 (0.48) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL8325843 | 0.81 | NPSR1 (0.48) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL11655595 | 0.81 | NPSR1 (0.48) | NPSR1GLO1ALDH1A1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9227970-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150099735-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-8946427-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2015-02-03 | — | — | US | disclosed |
| US-20140303141-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8410117-B2 | Imidazopyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8263584-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2011-09-29 | — | — | US | disclosed |
| US-8017604-B2 | Imidazopyridines | HOFFMANN-LA ROCHE INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | HOFFMANN-LA ROCHE, INC. | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303141-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE3A, PDE5A, PDE3B | NPSR1 681/4885GLO1 2829/4885ALDH1A1 390/4885 |
| US-20110237564-A1 | IMIDAZOPYRIMIDINE DERIVATIVES | PDE5A, PDE3B, PDE3A | NPSR1 1343/4885GLO1 3760/4885ALDH1A1 105/4885 |
| US-20110071128-A1 | NOVEL IMIDAZOPYRIDINES | PDE10A, PDE4A, PDE3A | NPSR1 538/4885GLO1 4202/4885ALDH1A1 372/4885 |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | NPSR1 425/4885GLO1 3221/4885ALDH1A1 511/4885 |
| US-20150099735-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE3A, PDE5A, PDE3B | NPSR1 681/4885GLO1 2829/4885ALDH1A1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.